ClinicalTrials.Veeva

Menu
O

Oviedo Medical Research | Oviedo, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tirzepatide
LY3298176
Testosterone Undecanoate
Metformin
Semaglutide
Linaclotide
JZP-110
Sugar
Lyrica
Cagrilintide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 35 total trials

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Active, not recruiting
Type 2 Diabetes
Drug: Semaglutide
Drug: Cagrilintide

This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study....

Active, not recruiting
Obesity
Diabetes Mellitus, Type 2
Drug: Placebo
Drug: Semaglutide

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Cagrilintide
Drug: Semaglutide

This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participan...

Active, not recruiting
Overweight
Type 2 Diabetes Mellitus
Drug: Placebo semaglutide
Drug: Placebo cagrilintide

The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.

Active, not recruiting
Overweight
Obesity
Drug: Tirzepatide
Drug: Placebo

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab (SAR440340)

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation...

Active, not recruiting
Functional Constipation
Irritable Bowel Syndrome With Constipation
Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Primary Objective:Primary population (former smokers cohort):* Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of ac...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Novo Nordisk logo
Lilly logo
Pfizer logo
AbbVie logo
Eisai logo
G
Jazz Pharmaceuticals logo
M
Sanofi logo
Bayer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems